QUÉBEC CITY, Feb. 3, 2014 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that presentations on
two of its oncology compounds, zoptarelin doxorubicin (AEZS-108) and
disorazol Z, will be made during the 11th International Symposium on GnRH, in Salzburg, Austria, February 9 -11, 2014.
The session will be held on Tuesday, February 11, 2014, in Hall A of the
Wyndham Hotel in Salzburg.
Presentations are scheduled as follows:
|
10:30 am
|
"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting Concept: Overview
of Clinical Results"
|
|
|
Speaker: Dr. Günter Emons, Chairman, Department of Obstetrics &
Gynaecology, Georg-August University Göttingen, Germany
|
|
|
|
|
11:00 am
|
"Zoptarelin Doxorubicin (AEZS-108) New Drug Targeting Concept: GnRH
Receptor Targeting in Triple-Negative Breast Cancer"
|
|
|
Speaker: Dr. Jörg B. Engel, Medical University of Regensburg, Department
of Gynaecology and Obstetrics, Germany
|
|
|
|
|
11:15 am
|
"New and Highly Potent Disorazol Z GnRH Conjugates: Concept and Mode of
Action"
|
|
|
Speaker: Dr. Babette Aicher, Director, Preclinical Development, Aeterna
Zentaris
|
|
|
|
|
11:45 am
|
"New and Highly Potent Disorazol Z GnRH Conjugates: Preclinical Results
in Endometrial Cancers"
|
|
|
Speaker: Dr. Carsten Gruendker, Department of Obstetrics & Gynaecology,
Georg-August University Göttingen, Germany
|
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing novel treatments in oncology and endocrinology. The
Company's pipeline encompasses compounds from drug discovery to
regulatory approval. For more information, visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to
the safe harbour provisions of the U.S. Securities Litigation Reform
Act of 1995. Forward-looking statements involve known and unknown risks
and uncertainties that could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the risk that safety and efficacy data
from any of our Phase 3 trials may not coincide with the data analyses
from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of its
products or product candidates, the ability of the Company to take
advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in
economic conditions. Investors should consult the Company's quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on
these forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments, unless required to do
so by a governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.
Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
gvallieres@aezsinc.com
Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com
Copyright CNW Group 2014